PPARγ gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Wan, Jing ^a   Xiong, Shixi ^a   Chao, Shengping ^a   Xiao, Jianming ^b   Ma, Yexin ^b   Wang, Jinghua ^c   Roy, Sabita ^c  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; GLUCOSE; INSULIN; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; LIPID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; ANGIOPLASTY; ATHEROSCLEROSIS; BLOOD; CHINA; EXON; GENETICS; GENOTYPE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; RESTENOSIS;

ADIPOSE TISSUE; AGED; ANGIOPLASTY; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BLOOD GLUCOSE; CHINA; CORONARY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PPAR GAMMA; TRIGLYCERIDES;

EID: 77952306247     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-13     Document Type: Article

References (29)

1. Issemann I, Green S. Activation of a number of the steroid receptor superfamily by peroxisome. Nature 1999, 347:645-650.
2. Varga T, Nagy L. Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma. European Journal of Clinical Investigation 2008, 38:695-707. 10.1111/j.1365-2362.2008.02022.x, 18837794.
3. Kliewer SA, Willson TM. The nuclear receptor PPARgamma-bigger than fat. Curr Opin Genet Dev 1998, 8:576-581. 10.1016/S0959-437X(98)80014-2, 9794815.
4. Vidal-Puig AJ, Considine RV, Jimenez-Linan M. Peroxisome proliferator- activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulatin by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422. 10.1172/JCI119424, 508081, 9153284.
5. Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000, 149:251-266. 10.1016/S0021-9150(99)00479-7, 10729375.
6. Marx N, Sukhova GM, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17-23. 1852950, 9665460.
7. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
8. Haraguchi G, Kobayashi Y, Brown ML, Tanaka A, Isobe M, Gianturco SH, Bradley WA. PPAR (alpha) and PPAR (gamma) activators suppress the monocyte- macrophage apoB-48 receptor. J Lipid Res 2003, 44:1224-1231. 10.1194/jlr.M300077-JLR200, 12700342.
9. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR-gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:377-386. 10.2174/156800605774370362, 16248830.
10. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26:917-932. 10.2337/diacare.26.3.917, 12610059.
11. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004, 44:397-405. 10.1177/0091270004263017, 15051748.
12. Eckel RH, Wassef M, Chait. A Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002, 105:138-143.
13. Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009, 11:330-337. 10.1111/j.1463-1326.2008.00965.x, 2748337, 19267711.
14. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:4312-4319. 10.1210/jc.2004-0190, 15356026.
15. Buzzetti R, Petrone A, Caiazzo AM. PPAR-{gamma}2 Pro12Ala Variant Is Associated with Greater Insulin Sensitivity in Childhood Obesity. Pediatr Res 2004, 5:147-150.
16. Schäffler A, Barth N, Schmitz G, Zietz B, Palitzsch KD, Schölmerich J. Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine 2001, 14:369-373. 10.1385/ENDO:14:3:369, 11444435.
17. Moffett SP, Feingold E, Barmada MM, Damcott CM, Marshall JA, Hamman RF, Ferrell RE. The C161-->T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor gamma. Metabolism 2005, 54:1552-1556. 10.1016/j.metabol.2005.05.025, 16253648.
18. Yan ZC, Zhu ZM, Shen CY, Zhao ZG, Ni YX, Zhong J, Nie H. Peroxisome proliferator-activated receptor gamma C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome. Zhonghua Yi Xue Za Zhi 2004, 84:543-547.
19. Wang XL, Janine O, Natalia D. Peroxisome proliferator-activated receptorγC161→T polymorphism and coronary artery disease. Circ Res 1999, 44:588-594.
20. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996, 19:38-41.
21. Naveed S, Ken W, Sniderman AD, Ralph AD. Comparison of the associations of apolipoprptein B and no-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metablic syndrome in the insulin resistence atherosclerosis study. Circulation 2004, 110:2687-2693. 10.1161/01.CIR.0000145660.60487.94, 15492304.
22. Blüher M, Klemm T, Gerike T, Krankenberg H, Schuler G, Paschke R. Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur J Endocrinol 2002, 146:545-551. 10.1530/eje.0.1460545, 11916624.
23. Liu Y, Yuan Z, Liu Y, Zhang J, Yin P, Wang D, Wang Y, Kishimoto C. PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J 2007, 154:718-724. 10.1016/j.ahj.2007.06.009, 17892998.
24. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003, 26:2181-2188. 10.2337/diacare.26.7.2181, 12832332.
25. Saely CH, Dyballa T, Vonbank A, Woess M, Rein P, Beer S, Jankovic V, Boehnel C, Aczel S, Drexel H. Type 2 diabetes but not coronary atherosclerosis is an independent determinant of impaired mobility in angiographied coronary patients. Diabetes Res Clin Pract 2008, 82:185-189. 10.1016/j.diabres.2008.08.007, 18829127.
26. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it?. Lancet 1997, 350:4-9. 10.1016/S0140-6736(97)90021-0, 9217711.
27. Taubert G, Winkelmann BR, Schleiffer T, März W, Winkler R. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003, 145:19519-19527.
28. Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: An angiographic study. Atherosclerosis 2008, 199:317-322. 10.1016/j.atherosclerosis.2007.11.020, 18187138.
29. Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scallissi N, Speranza AC, Gomes S, Hirata MH. Effect of the peroxisome proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. J Endocrinol Invest 2005, 28:129-136.